Abstract
Introduction Use of the mechanically expandable transcatheter aortic valve (MEV) has been recently linked to increased risks of valve dysfunction and cardiovascular mortality. The risk of developing conduction disturbance with the MEV valve is well-known, and the negative prognostic impact of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) is another consideration.
Aim This study aimed to compare the mid-term survival of patients with MEV and self-expandable valves (SEV), and to examine survival of both groups according to the presence or absence of PPI.
Methods This single-center, retrospective, observational study examined data from MEV and SEV groups comprising 92 and 373 patients, respectively. The mean clinical follow-up was 2.5 ± 1.7 years. Mortality information was obtained from the National Institutes of Health Information and Statistics.
Results Baseline characteristics were comparable between the groups. The log-rank test showed higher cardiovascular mortality in the MEV group [p=0.042; RR: 1.594 (95%CI: 1.013-2.508)]. The Cox proportional hazards model identified MEV implantation as an independent predictor of cardiovascular mortality. The rate of PPI was twice as high in the MEV versus SEV group (33.7% vs. 16.1%; p <0.001). We compared the survival of both groups according to the presence or absence of PPI and found higher mortality in the MEV group without PPI versus the SEV group without PPI (p=0.007; RR: 2.156 [95%CI: 1.213-3.831]). Survival did not differ in the groups with PPI.
Conclusions A higher mid-term cardiovascular mortality rate was observed with MEV versus SEV implants. Comparing both groups according to the presence or absence of PPI, we observed a higher mortality risk in patients with MEV without PPI than in SEV without PPI. In contrast, mortality did not differ between the groups when PPI was implanted.
What is already known on this topic Use of the mechanically expandable transcatheter aortic valve (MEV) has been recently linked to increased risks of valve dysfunction and cardiovascular mortality. The risk of developing conduction disturbance with the MEV valve is well-known, and the negative prognostic impact of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation is another consideration.
What this study adds Our study suggested that higher cardiovascular mortality was independently associated with the use of MEV versus self-expandable valves (SEV) implants. Comparing both groups according to the presence or absence of PPI, we observed a higher mortality risk in patients with MEV without PPI than in those with SEV without PPI.
How this study might affect research, practice or policy Although MEV were recalled in 2020, thousands of patients have been treated with them. Therefore, patients with MEV without PPI deserve increased attention during long-term follow-up.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ministry of Health, Czech Republic (Conceptual Development of Research Organization), Motol University Hospital, Prague Czech Republic 00064203
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague gave ethical approval for this work on 3rd November 2021 (EK-1312/21)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This study was supported by the Ministry of Health, Czech Republic–Conceptual Development of Research Organization, Motol University Hospital, Prague Czech Republic 00064203
Disclosures: The authors declare no conflict of interest.
Data Availability
All data produced in the present work are contained in the manuscript
